SENS-401 (R-Azasetron Besylate)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hearing Loss
Conditions
Hearing Loss
Trial Timeline
Aug 10, 2022 → May 31, 2024
NCT ID
NCT05258773About SENS-401 (R-Azasetron Besylate)
SENS-401 (R-Azasetron Besylate) is a phase 2 stage product being developed by Sensorion for Hearing Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT05258773. Target conditions include Hearing Loss.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05628233 | Phase 2 | Completed |
| NCT05258773 | Phase 2 | Completed |
Competing Products
6 competing products in Hearing Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CGF166 | Novartis | Phase 1/2 | 41 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| PF-04958242 + PF-04958242 + Placebo | Biogen | Phase 1 | 30 |
| PIPE-505 + Placebo | Contineum Therapeutics | Phase 1/2 | 33 |
| SENS-401 + SENS-401 | Sensorion | Phase 2/3 | 57 |
| SENS-401 (R-Azasetron Besylate) | Sensorion | Phase 2 | 44 |